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Abstract
Background: A trial was commissioned to evaluate the effectiveness of larval therapy to debride
and heal sloughy and necrotic venous leg ulcers. Larval therapy in the trial was to be delivered in
either loose or bagged form. Researchers were concerned that resistance to larval therapy may
threaten the feasibility of the trial. Additionally there was concern that the use of larval therapy
may require a larger effect size in time to healing than originally proposed by the investigators.
Methods: To formally evaluate patient preferences a survey using two randomly allocated, nurse
administered questionnaires was undertaken. Patients were randomised to receive one of the two
following questionnaires (i) preferences between loose larvae and standard treatment (hydrogel)
or (ii) patient preferences between bagged larvae and standard therapy (hydrogel). The study was
undertaken in a Vascular Clinic, in an Outpatients Department of a large teaching hospital in the
North of England. The sample consisted of 35 people aged 18 years and above with at least one leg
ulcer of venous or mixed (venous and arterial) aetiology.
Results: Approximately 25% of participants would not consider the use of larval therapy as an
acceptable treatment option for leg ulcers, regardless of the method of containment.
For the patients that would consider the use of larval therapy, different preferences in healing times
required to use the therapy were observed depending upon the method of containment. The
median response of those participants questioned about bagged larvae found that they would be
willing to use this therapy even if they were equally able to achieve healing with the use of hydrogel
by 20 weeks. For those participants questioned about the use of loose larvae complete healing
would have to have taken place over 17 weeks for them to choose larvae as their preferred option
rather than hydrogel. This difference was not significant (p = 0.075).
Conclusion: We found no evidence of widespread resistance to the utilisation of larval therapy
from patients regardless of the method of larval therapy containment. These methods have the
potential to inform sample size calculations where there are concerns of patient acceptability.
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Whilst there is some evidence that larval treatment effec-
tively debrides wounds (i.e. removes necrotic tissue) [1],
there is no evidence from randomised trials that larval
therapy accelerates the healing of chronic wounds. Conse-
quently in 2004, the NHS Health Technology Assessment
programme commissioned a pragmatic RCT to evaluate
whether larval therapy will accelerate the healing of
chronic necrotic venous leg ulcers [2]. Larval therapy can
be delivered in two forms: loose larvae that are placed
directly onto the wound or bagged larvae that are con-
tained in a small gauze bag on the wound. It might be pre-
sumed that the latter is more acceptable to participants
since there is less chance of the larvae 'escaping' from the
wound area and the larvae are mainly hidden from view.
However, bagged and loose larvae may not have equiva-
lent effects on healing. Therefore it is important to test
both the acceptability and the effectiveness of the two
methods of delivery.
Researchers involved in the RCT [2] were concerned that
participants may have an aversion to treatment by larval
therapy and if this was the case, it may threaten the feasi-
bility of research using larval therapy. In this paper we
describe a survey undertaken to determine the patient
acceptability of larval therapy and to elicit the effect size
in time to healing required by participants to accept larval
therapy in one of two delivery mechanisms to a standard
therapy (a hydrogel).
A key design issue for the trialists was defining the clini-
cally important difference in healing time between (1) lar-
val therapy and standard treatment (hydrogel), and (2)
between the two different methods of delivering larvae
(bagged or loose) to be used in the sample size calcula-
tion. In the original trial application, we sought a median
difference in time to healing of 6 weeks between standard
treatment and larval therapy. This was based partly on
clinical experience [3] and partly on the costs of larval
therapy. Participants' views on the desired treatment effect
were not taken into account at this point. Although there
is a body of literature on eliciting patient preferences in
health care [4,5] we have not identified an evaluation
designed to inform the sample size of another study.
Methods
We undertook a survey of patient preferences using ran-
domised allocation of two questionnaires. Both question-
naires asked about preferences between larval therapy and
standard treatment (hydrogel) if hydrogel dressings were
to heal their ulcer in 20 weeks and the larvae were to heal
their ulcer over a range of times (between 6 and 20
weeks). One questionnaire asked about preferences for
loose larvae or hydrogel at a range of healing times for
loose larvae, the other questionnaire asked about prefer-
ences between bagged larvae and hydrogel for a range of
healing times for bagged larvae. In both cases, the healing
time for hydrogel was set at 20 weeks.
Research governance and local ethics committee approval
was granted for the research. All participants were asked to
provide informed consent and were reassured of the con-
fidentially and anonymity of their responses.
We randomised participants to receive the 'bagged' or
'loose' questionnaire using sealed opaque envelopes
which were sequentially numbered. Envelopes were left
with the outpatient clinic's receptionist. Participants were
taken to a private room to discuss participation and fol-
lowing consent the envelope (next in sequence) was
opened in the presence of the patient. In addition, the
number sequence was held by a remote researcher who
could check patient number with allocation. Both ques-
tionnaires were administered by a nurse researcher (KS).
Initially participants were asked if they would consider the
use of larval therapy as a therapy if their nurse or doctor
recommended use of them. Patient characteristics were
recorded for all participants. If participants were unwilling
to consider the use of larval therapy no further questions
about the therapy were asked. For those participants who
responded that they would consider the use of larval ther-
apy further questions were asked to determine what differ-
ence in healing time relative to hydrogel they would
require to utilise larval therapy or not mind which therapy
they received.
Firstly participants were asked to choose which treatment
that they would prefer to receive if both hydrogel and lar-
val therapy achieved healing at 20 weeks: hydrogel, larval
therapy or no preference. If the patient responded that
they would prefer larval therapy or that they had no pref-
erence at this point no further questions were asked. Then
in order to minimise the number of questions presented
from a maximum of 15 to a maximum of 8, the second
scenario presented was one in which larval therapy would
heal the ulcer at 12 weeks (i.e. an 8 week difference). If on
asking this question larval therapy was preferred or there
was no preference, the next set of questions would ask
about the preference between therapies if healing
occurred at decreasing times with the use of larval therapy
i.e. 19, 18, 17, 16, 15, 14 and 13 weeks. If, on the other
hand, the patient did not prefer larval therapy over hydro-
gel with an 8 week difference in time to healing, then
decreasing times to healing with the use of larval therapy
were presented, i.e. healing at 11, 10, 9, 8, 7 and 6 weeks
(increasing effect sizes from 9 to 14 weeks). The first time
point at which the patient had no preference or chose lar-
val therapy was then recorded and used in the analysis.Page 2 of 4
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A total of 35 participants were included in the study
allowing us to detect, with 80% power (2 sided p = 0.05),
one standard deviation difference in healing times
between the two modes of larval therapy.
As the data were skewed we used a Mann-Whitney U test
to determine if the differences between the median times
to healing derived for loose larvae versus hydrogel and
bagged larvae versus hydrogel were statistically signifi-
cant.
Results
Participants
Forty-one participants with leg ulcers, attending a Vascu-
lar Clinic, in an Outpatients Department of a large teach-
ing hospital in the North of England, were approached to
take part in the study and thirty five participants aged 18
years and above, with at least one leg ulcer of venous or
mixed (venous and arterial) aetiology, agreed to take part.
Eighteen participants were allocated to the bagged ques-
tionnaire and 17 to the loose larval therapy questionnaire.
Table 1 shows the characteristics of the participants ran-
domised to the different surveys.
The majority of leg ulcer participants interviewed (27/35,
77%) stated that they would consider the use of larval
therapy, irrespective of the method of containment. How-
ever, almost a quarter of participants (8/35) stated that
they would never consider the use of larval therapy, four
people in each group. These participants were not asked
any further questions about the use of larval therapy.
The difference between hydrogel and larvae healing times
required for patients to choose bagged larvae over hydro-
gel ranged from 0 to 8 weeks, with a median value of 0,
indicating that no reduction in healing time would be
required for participants to choose bagged larval therapy
over hydrogel. However, the difference in hydrogel and
larvae healing times required for patients to chose loose
larvae over hydrogel ranged from 0 to 12 weeks, with a
median difference in healing times of 3 weeks, indicating
that complete healing would have to be achieved in 17
weeks (median) for loose larvae, in order for this to be
preferred over hydrogel.
The 3 week difference in effect sizes required to choose lar-
vae in preference to hydrogel between the loose and the
bagged larval therapy groups was not statistically signifi-
cant (p = 0.075) Table 2 shows the differences between
the groups of those participants who would consider lar-
val therapy.
Discussion
We have undertaken a study of the effect sizes deemed
important by participants who would consider larval ther-
apy for leg ulcer treatment. Our study failed to find evi-
dence of a widespread resistance to the idea of using
larvae as a treatment for leg ulcers. Irrespective of the
method of containment of the larvae, a similar proportion
of participants (approximately three quarters) would con-
sider the use of larval therapy. It is difficult to compare
this treatment refusal rate with other studies as larvae are
vastly different to other existing therapies for the treat-
ment of leg ulcers.
No significant difference was observed in the time to heal-
ing required by patients to choose larvae, either loose or
bagged, in preference to hydrogel. A possible reason for
this non-significant result may be the study power, as our
initial sample size calculation did not allow for 25% of
participants to refuse consideration of larval therapy (cli-
nicians estimated 10% refusal rate).
Conclusion
Our study found that patients did not have a widespread
resistance to the idea of using larval therapy for the treat-
ment of their leg ulcers, regardless of the method of con-
tainment of the larvae. Furthermore, we found that
participants were willing to have a much smaller median
difference in time to healing than the six weeks proposed
by clinicians, and used in the original sample size for the
study. As such, researchers were able to feel confident in
the patient acceptability of the intervention as the original
sample size proposed greater differences in time to heal-
ing than that proposed by participants.
Table 1: Characteristics of patients surveyed
Loose larvae questionnaire Bagged larvae questionnaire
Gender
Male 8 11
Female 9 7
Mean age of participants, (SD) 73.29 years (10.09) 68.56 years (12.05)
Range 57–93 years 46–92 years
Mean duration of current ulcer (SD) 3.18 years (3.95) 3.04 years (3.1)
Range 2 months–14 years 3 months–12 yearsPage 3 of 4
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We found that using a relatively simple, interviewer
administered questionnaire we could elicit meaningful
information on the effect size for an intervention from
participants. This method has the potential to elicit infor-
mation to be used in sample size calculations for ran-
domised trials in cases where there is concern over the
patient acceptability of a therapy. It would be useful to
repeat this exercise for interventions that may have signif-
icant drawbacks to the patient as well as potential bene-
fits.
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Table 2: Differences in healing times required to prefer larvae 
over hydrogel
Loose Bagged p-value
Interquartile range 0–5 0–1.75
Median 3 0 0.075
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